Literature DB >> 33522784

Central nervous system prophylaxis in diffuse large B-cell lymphoma: a race to the bottom.

Mark Roschewski1.   

Abstract

Entities:  

Year:  2021        PMID： 33522784      PMCID： PMC7849335          DOI： 10.3324/haematol.2020.266635

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.

Authors:  Toby A Eyre; Amy A Kirkwood; Julia Wolf; Catherine Hildyard; Carolyn Mercer; Hannah Plaschkes; John Griffith; Paul Fields; Arief Gunawan; Rebecca Oliver; Stephen Booth; Nicolas Martinez-Calle; Andrew McMillan; Mark Bishton; Christopher P Fox; Graham P Collins; Chris S R Hatton
Journal:  Br J Haematol       Date:  2019-06-20       Impact factor: 6.998

2.  Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma.

Authors:  David D W Twa; Derrick G Lee; King L Tan; Graham W Slack; Susana Ben-Neriah; Diego Villa; Joseph M Connors; Laurie H Sehn; Anja Mottok; Randy D Gascoyne; David W Scott; Christian Steidl; Kerry J Savage
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

Review 3.  The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.

Authors:  Costas D Arvanitis; Gino B Ferraro; Rakesh K Jain
Journal:  Nat Rev Cancer       Date:  2019-10-10       Impact factor: 60.716

4.  Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Authors:  H Ghesquieres; M Chevrier; M Laadhari; O Chinot; S Choquet; C Moluçon-Chabrot; P Beauchesne; R Gressin; F Morschhauser; A Schmitt; E Gyan; K Hoang-Xuan; E Nicolas-Virelizier; N Cassoux; V Touitou; M Le Garff-Tavernier; A Savignoni; I Turbiez; V Soumelis; C Houillier; C Soussain
Journal:  Ann Oncol       Date:  2019-04-01       Impact factor: 32.976

5.  Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.

Authors:  Magdalena Klanova; Laurie H Sehn; Isabelle Bence-Bruckler; Federica Cavallo; Jie Jin; Maurizio Martelli; Douglas Stewart; Umberto Vitolo; Francesco Zaja; Qingyuan Zhang; Federico Mattiello; Gila Sellam; Elizabeth A Punnoose; Edith Szafer-Glusman; Christopher R Bolen; Mikkel Z Oestergaard; Guenter R Fingerle-Rowson; Tina Nielsen; Marek Trneny
Journal:  Blood       Date:  2019-01-07       Impact factor: 22.113

6.  The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper.

Authors:  Pamela McKay; Matthew R Wilson; Sridhar Chaganti; Jeffery Smith; Christopher P Fox; Kate Cwynarski
Journal:  Br J Haematol       Date:  2020-07-15       Impact factor: 6.998

7.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

8.  Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Authors:  Anas Younes; Laurie H Sehn; Peter Johnson; Pier Luigi Zinzani; Xiaonan Hong; Jun Zhu; Caterina Patti; David Belada; Olga Samoilova; Cheolwon Suh; Sirpa Leppä; Shinya Rai; Mehmet Turgut; Wojciech Jurczak; Matthew C Cheung; Ronit Gurion; Su-Peng Yeh; Andres Lopez-Hernandez; Ulrich Dührsen; Catherine Thieblemont; Carlos Sergio Chiattone; Sriram Balasubramanian; Jodi Carey; Grace Liu; S Martin Shreeve; Steven Sun; Sen Hong Zhuang; Jessica Vermeulen; Louis M Staudt; Wyndham Wilson
Journal:  J Clin Oncol       Date:  2019-03-22       Impact factor: 44.544

9.  CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Authors:  Norbert Schmitz; Samira Zeynalova; Maike Nickelsen; Roopesh Kansara; Diego Villa; Laurie H Sehn; Bertram Glass; David W Scott; Randy D Gascoyne; Joseph M Connors; Marita Ziepert; Michael Pfreundschuh; Markus Loeffler; Kerry J Savage
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

10.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.